17 Aug Risk of dopamine dysregulation syndrome (DDS) associated with the use of dopaminergic medicines used for the treatment of Parkinson’s disease (PD).
Posted at 12:37h
in
The pharmaceutical companies mentioned below, in collaboration with South African Health Products Regulatory Authority (SAHPRA), wish to inform you of the risk of dopamine dysregulation syndrome (DDS) associated with the chronic use of dopaminergic medicines used for the treatment of Parkinson’s disease. The Professional Information (PI) and Patient Information Leaflet (PIL) of these products will be amended to reflect this safety issue.
2021 Nov
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
25/11/2021
File Type:
pdf
Category:
Communication To Health Care Professionals